Cartesian Therapeutics (RNAC) Non Operating Income (2024 - 2026)

Cartesian Therapeutics (RNAC) has 3 years of Non Operating Income data on file, last reported at -$12.7 million in Q1 2026.

• On a quarterly basis, Non Operating Income fell 403.49% year-over-year to -$12.7 million in Q1 2026; TTM through Mar 2026 was -$13.0 million, a 189.85% decrease from a year earlier, with the FY2025 full-year figure at $3.9 million, up 111.76% from the prior year.
• Non Operating Income for Q1 2026 stood at -$12.7 million, up from -$23.1 million in the prior quarter.
• Over the last five years, Non Operating Income for RNAC reached as high as $37.7 million in Q2 2025 and fell as low as -$43.5 million in Q1 2024.
• Historically, Non Operating Income has averaged -$4.7 million across 3 years, with a median of -$6.6 million in 2024.
• Across the five-year window, Non Operating Income surged 47617.72% in 2025 and sank 403.49% in 2026, its largest moves.
• Year by year, Non Operating Income stood at $16.8 million in 2024, then slumped by 237.97% to -$23.1 million in 2025, then surged by 45.17% to -$12.7 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were -$12.7 million in Q1 2026, -$23.1 million in Q4 2025, and -$14.8 million in Q3 2025.